文献速递肾小球疾病慢性肾脏病遗传性与小管间质肾病

从数据到药物:英国罕见肾病国家登记系统RaDaR的转化影响

From data to drug: the translational impact of RaDaR, the UK national registry of rare kidney diseases.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

罕见肾病种类多、单个病种患者少,治疗开发受诊断困难、试验样本量小及缺乏监管认可的疾病特异性终点限制。RaDaR分析量化了IgA肾病等肾小球疾病进展风险,支持蛋白尿降低作为监管批准的替代终点,并为NICE评估和针对特定分子亚组的临床试验提供依据。

要点

  • RaDaR分析支持蛋白尿降低作为IgA肾病等肾小球疾病监管批准的替代终点。
  • RaDaR为NICE评估及针对特定分子亚组的临床试验提供数据支持。

核心结论

  • RaDaR证明国家登记系统可桥接真实世界数据与治疗开发,加速罕见肾病从疾病理解到药物批准的路径。

主要发现

  • RaDaR支持流行病学研究、生物标志物与基因组研究、临床试验可行性与招募、患者报告体验研究及健康经济学评价。
  • RaDaR分析帮助量化IgA肾病和其他肾小球疾病的进展风险,支持蛋白尿降低作为监管批准的替代终点。
  • RaDaR数据为NICE评估提供信息,并支持针对特定分子亚组的临床试验。
  • RaDaR在局灶节段性肾小球硬化、Alport综合征和C3肾小球病试验中的作用体现其对精准肾脏病学的贡献。

临床怎么用

  • 临床可利用RaDaR等登记系统数据理解罕见肾病自然史、评估进展风险并设计临床试验。
  • 蛋白尿降低可作为IgA肾病等肾小球疾病监管批准的替代终点依据。
  • 对最罕见疾病,需国际协作以获得充分把握度的数据集和统一终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Each rare kidney disease affects relatively few individuals, but collectively these disorders place a significant burden on patients, families, healthcare systems and society. Historically, therapeutic development has been limited by diagnostic challenges, small and underpowered trials, and a lack of disease-specific, clinically meaningful endpoints acceptable to regulators. The UK National Registry of Rare Kidney Diseases (RaDaR) was launched in 2010 to address these challenges by capturing high-quality longitudinal data. With over 37 000 participants enrolled across more than 100 UK sites, RaDaR now functions as a nationally integrated research platform supporting epidemiological studies, biomarker and genomic research, clinical trial feasibility and recruitment, patient-reported experience studies, and health economic evaluations. RaDaR's infrastructure and stakeholder engagement have advanced understanding of disease natural history and surrogate endpoints, and have informed trial design. Analyses from RaDaR have helped quantify progression risk in immunoglobulin A nephropathy and other glomerulopathies, supporting proteinuria reduction as a surrogate endpoint for regulatory approval. RaDaR data have informed National Institute for Health and Care Excellence (NICE) appraisals and supported clinical trials targeting specific molecular subgroups. By integrating clinical, laboratory and hospital episode data, and by maintaining sustained patient engagement, RaDaR enables research that is both scalable and patient-centred. Its role in trials for focal segmental glomerulosclerosis, Alport syndrome and C3 glomerulopathy exemplifies its contribution to precision nephrology. For the rarest conditions, international collaboration remains essential to achieve adequately powered datasets and harmonized endpoints. RaDaR demonstrates how a national registry can bridge the gap between real-world data and therapeutic development, accelerating the path from disease understanding to drug approval in rare kidney disease.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Gale DP. From data to drug: the translational impact of RaDaR, the UK national registry of rare kidney diseases. Nephrol Dial Transplant. 2026. PMID: 41137724. doi:10.1093/ndt/gfaf227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。